Pharmaceutical Industry Reports

Aurobindo Pharma, on February 23, announced that the US FDA had imposed a ban on shipments from one of its unit; following which the stock tumbled 17 per cent. It has plummeted 26 per cent over last week accompanied with heavy volumes and is currently testing its significant long-term support band between Rs 155 and Rs 165.

Medivir has reported positive results from the Phase 2b study of TMC435 in treatment-naïve patients with hepatitis C virus (HCV) genotype-1.

Otonomy, Inc., a developer of innovative therapeutics for disorders of the ear, today announced the appointments of G. Michael Wall, Ph.D., as the company's vice president of product development and Cindy Berejikian as the company's vice president of program management.

Opinions are divided, however, over whether the industry’s problems make it one to avoid or a great place to look for undervalued, out-of-favor stocks.

South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given Asian tiger status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS (1) See IP Multimedia Subsystem.